# Oncoheroes Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncoheroes-bioscience

- Industry: Biotechnology
- Headquarters: Brookline, US
- Website: www.oncoheroes.com
- Total disclosed funding: $1.1M
- Latest round: Seed (Mar 12, 2020)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2017 by CEO Ricardo Garcia and COO Cesare Spadoni, Marc Goldberg JD, Marco Muñoz, Oncoheroes Bioscience Inc. is a biotech company focused on childhood cancer by identifying and developing projects to create new treatments and drugs. In March 2020, Oncoheroes Science, Inc. raised USD 1.1 million in seed funding from DREAMERS Ventures. The company has a discovery lab in Barcelona, Spain. In November 2021, Oncoheroes Biosciences Inc. out-licensed Volasertib, a Polo-like kinase 1 (PLK-1) inhibitor with evidence of clinical activity in relapsed/refractory acute myeloid leukemia (AML), to Notable Labs, Inc. for the global adult development of its anticancer therapy. Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer.

The company develops pediatric oncology drugs for children. The company is working on creating and exploring new generations of highly targeted medications for certain tumors that include diffuse intrinsic pontine glioma (DIPG), atypical teratoid rhabdoid tumor (ATRT), medulloblastoma, acute myeloid leukemia, neuroblastoma, rhabdomyosarcoma, ewing’s sarcoma, osteosarcoma.

## Funding rounds

- Seed, Mar 12, 2020, $1.1M — DREAMERS Ventures

## Investors

- DREAMERS Ventures (https://capitalatlas.ai/funds/dreamers-ventures) — Seed